Table 1.
Baseline characteristics of patients with AAV (n = 60)
| Values | |
|---|---|
| Classification, n (%) | |
| MPA | 32 (53.3) |
| GPA | 17 (28.3) |
| EGPA | 11 (18.3) |
| Demographic data | |
| Age, years | 59.4 (14.3) |
| Female gender, n (%) | 40 (66.7) |
| New onset AAV, n (%) | 23 (38.3) |
| Disease duration, months† | 2.4 (23.9) |
| AAV-related parameter | |
| BVAS† | 7.0 (10.5) |
| FFS (2009) † | 1.0 (1.0) |
| VDI† | 3.0 (2.0) |
| SF-36 PCS score | 50.5 (22.4) |
| SF-36 MCS score | 58.3 (20.1) |
| Clinical features (organ involvement), n (%) | |
| General manifestation | 17 (28.3) |
| Cutaneous manifestation | 7 (11.7) |
| Mucous membrane and eye manifestation | 3 (5.0) |
| Ear, nose, and throat manifestation | 25 (41.7) |
| Pulmonary manifestation | 37 (61.7) |
| Cardiovascular manifestation | 3 (5.0) |
| Abdominal manifestation | 1 (1.7) |
| Renal manifestation | 33 (55.0) |
| Nervous system manifestation | 12 (20.0) |
| ANCA positivity, n (%) | |
| ANCA double positivity | 1 (1.7) |
| MPO-ANCA (or P-ANCA) positivity | 37 (61.7) |
| PR3-ANCA (or C-ANCA) positivity | 7 (11.7) |
| ANCA negativity | 17 (28.3) |
| Laboratory data | |
| White blood cell count, /mm3† | 7345.0 (5380.0) |
| Neutrophil count, /mm3† | 5000.0 (4790.0) |
| Platelet count, × 1000/mm3† | 254.0 (139.0) |
| ESR, mm/h† | 30.0 (31.5) |
| CRP, mg/L† | 1.4 (8.1) |
| Creatinine, mg/dL† | 1.0 (1.4) |
| AST, IU/L† | 18.0 (7.0) |
| ALT, IU/L† | 18.5 (13.5) |
| Serum YKL-40, ng/mL† | 189.2 (190.7) |
| Concurrent immunosuppressive agents, n (%) | |
| Glucocorticoid | 42 (70.0) |
| Cyclophosphamide | 8 (13.3) |
| Rituximab | 1 (1.7) |
| Azathioprine | 14 (23.3) |
| Tacrolimus | 3 (5.0) |
| Mycophenolate mofetil | 2 (3.3) |
| Methotrexate | 2 (3.3) |
Values are expressed as mean (standard deviation) or in number (percentages)
†Continuous variables that were non-normally distributed are expressed as median (interquartile range)
AAV ANCA-associated vasculitis, ANCA anti-neutrophil cytoplasmic antibody, MPA microscopic polyangiitis, GPA granulomatosis with polyangiitis, EGPA eosinophilic granulomatosis with polyangiitis, BVAS Birmingham vasculitis activity score, FFS Five factor score, VDI Vasculitis damage index, SF-36 Short form-36, PCS Physical component summary, MCS Mental component summary, MPO myeloperoxidase, P perinuclear, PR3 proteinase 3, C cytoplasmic, ESR erythrocyte sedimentation rate, CRP C-reactive protein, AST aspartate aminotransferase, ALT alanine aminotransferase